Literature DB >> 29913105

Generalized ROC methods for immunogenicity data analysis of vaccine phase I studies in a seropositive population.

Li Yu1, Mark T Esser2, Judith Falloon3, Tonya Villafana2, Harry Yang1.   

Abstract

Immunogenicity data from phase 1 vaccine studies can be difficult to interpret, especially in seropositive populations and when multiple assays are used. We developed 3 statistical methods (Youden index [YI] threshold, receiver-operating characteristic relative to baseline [ROC-B], and ROC of postdose levels [ROC-P]) to characterize complex immunogenicity data by assessing the proportion of a study population that achieved values above thresholds. The YI method calculates a single threshold per assay. Both ROC methods construct ROC curves for individual assays and surfaces for assay combinations to assess degree of separation of postdose values from a reference distribution; the ROC-B method uses overall predose values as the reference distribution and the ROC-P method uses pooled postdose values. All methods are applicable to a seropositive population with overlapping distributions of baseline and postdose measurements and can evaluate results of multiple assays jointly. The ROC-P method is also applicable when postdose levels are fully separated from baseline levels, as is common in a seronegative population. These methods were demonstrated using data from a phase 1a study of respiratory syncytial virus vaccines formulated with and without an adjuvant in a seropositive population of adults aged ≥60 years. All 3 methods provided a comprehensive assessment of vaccine immunogenicity effects with results presented in easily interpretable formats. In the example data, the methods demonstrated antigen dose response trend and contribution of adjuvant to response in multiple assays individually and jointly where optimal responses in assay combinations (humoral and cellular) are important.

Entities:  

Keywords:  Dose selection; receiver-operating characteristic; seropositive; statistical analysis; vaccine; youden index

Year:  2018        PMID: 29913105      PMCID: PMC6314430          DOI: 10.1080/21645515.2018.1489191

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  24 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

Review 2.  Statistical considerations for vaccine immunogenicity trials. Part 1: Introduction and bioassay design and analysis.

Authors:  Brian D Plikaytis; George M Carlone
Journal:  Vaccine       Date:  2005-02-18       Impact factor: 3.641

Review 3.  Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.

Authors:  Sandra Romero-Steiner; Carl E Frasch; George Carlone; Roland A Fleck; David Goldblatt; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2006-02

4.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

Review 5.  Challenges in early clinical development of adjuvanted vaccines.

Authors:  Giovanni Della Cioppa; Ingileif Jonsdottir; David Lewis
Journal:  Vaccine       Date:  2015-06-08       Impact factor: 3.641

6.  Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers.

Authors:  Robert M Jacobson; Diane E Grill; Ann L Oberg; Pritish K Tosh; Inna G Ovsyannikova; Gregory A Poland
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

8.  Comparison of influenza serological techniques by international collaborative study.

Authors:  J M Wood; R E Gaines-Das; J Taylor; P Chakraverty
Journal:  Vaccine       Date:  1994-02       Impact factor: 3.641

9.  Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.

Authors:  Hilary A Robbins; Troy J Kemp; Carolina Porras; Ana Cecilia Rodriguez; Mark Schiffman; Sholom Wacholder; Paula Gonzalez; John Schiller; Douglas Lowy; Sylviane Poncelet; Mark Esser; Katie Matys; Allan Hildesheim; Ligia A Pinto; Rolando Herrero; Mahboobeh Safaeian
Journal:  Front Oncol       Date:  2014-01-13       Impact factor: 6.244

10.  Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus.

Authors:  Sarah V Maifeld; Bodrey Ro; Hoyin Mok; Marla Chu; Li Yu; Ryan Yamagata; Tansy Leonardson; Vera Chio; Bandita Parhy; Samuel Park; Marcia Carlson; Shushil Machhi; Nancy Ulbrandt; Ann R Falsey; Edward E Walsh; C Kathy Wang; Mark T Esser; Fengrong Zuo
Journal:  PLoS One       Date:  2016-04-12       Impact factor: 3.240

View more
  1 in total

1.  Protective efficacy of an attenuated Mtb ΔLprG vaccine in mice.

Authors:  Amanda J Martinot; Eryn Blass; Jingyou Yu; Malika Aid; Shant H Mahrokhian; Sara B Cohen; Courtney R Plumlee; Rafael A Larocca; Noman Siddiqi; Shoko Wakabayashi; Michelle Gardner; Rebecca Audette; Anne Devorak; Kevin B Urdahl; Eric J Rubin; Dan H Barouch
Journal:  PLoS Pathog       Date:  2020-12-14       Impact factor: 6.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.